Formycon secures CDMO partner for global biosimilar production

15-Jul-2026 - Formycon AG and OneSource Specialty Pharma Limited, a multi-modality specialty pharma CDMO, announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and ...

11th Life Science Pitch Day at the IZB: Connecting Startups with Capital, Expertise and Industry Networks

Twelve selected start-ups and project teams presented their approaches to addressing diseases with high medical need

08-Jul-2026 - The Innovation and Start-up Center for Biotechnology (IZB), together with High-Tech Gründerfonds (HTGF) and with the support of Leaps by Bayer, Boehringer Ingelheim Venture Fund and MEDICE – The Health Family, hosted the 11th Life Science Pitch Day at the IZB. The well-established format once ...

Rentschler Biopharma appoints Dr. Torsten Woehr as CEO

Dr. Torsten Woehr brings over 25 years of CDMO experience with strong international expertise

03-Jul-2026 - Rentschler Biopharma SE announced the appointment of Torsten Woehr as Chief Executive Officer (CEO), effective August 1, 2026.Torsten Woehr brings more than 25 years of experience across the international CDMO and biotechnology industry, combining strong commercial leadership with deep ...

Merck Announces Hiba Therapeutics as Winner of 2026 North American Advance Biotech Grant

With TROIKA, the Boston-based start-up is developing a programmable T-cell engager platform to combat solid tumours

26-Jun-2026 - Merck announced Hiba Therapeutics as the winner of the 2026 North American Advance Biotech Grant at the 2026 BIO International Convention. Boston-based Hiba Therapeutics is developing TROIKA T Cell Engagers, a modular, programmable biologics platform that activates tumor-resident T cells to ...

Anaveon brings in ex-CureVac executive to lead immunology push

13-Apr-2026 - Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announced the appointment of Thaminda Ramanayake as its new Chief Executive Officer. Mr. Ramanayake brings over 20 years of global biopharmaceutical leadership experience, with a strong ...

Sartorius is counting on a biopharma boom by 2030

Biologics are expected to account for 57 per cent of pharmaceutical sales

20-Mar-2026 - The life science group Sartorius is sharpening its strong focus on biopharma customers and outlines its updated strategy and new mid-term financial targets ahead oftoday’s Capital Markets Day, setting out a clear path to sustained above-market growth. “Our resilient business model and success ...

Start-up AveThera acquires Fraunhofer site for biologics production

The young biotech company takes over pharmaceutical biotechnology unit including employees

18-Mar-2026 - The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM has successfully completed the sale of its site in Braunschweig to AveThera GmbH. As a result of the sale, the site in Braunschweig will now be taken over by a young company that wants to use the existing expertise and ...

Stopping immune aging: Startup receives million-dollar investment

Groundbreaking thymus-rejuvenating biologics are designed to restore immune function and promote lasting immune health throughout all stages of life

12-Jan-2026 - TECregen, a biotechnology company pioneering thymus regeneration, announced the successful completion of a CHF 10 million (∼EUR 10.7 million / USD 12.6 million) seed financing round. The financing was led by the Boehringer Ingelheim Venture Fund (BIVF), with participation from LifeSpan Vision ...

WACKER and start-up Gearbox Biosciences announce strategic collaboration

The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA)

11-Aug-2025 - Wacker Chemie AG and OÜ Gearbox Biosciences announced a strategic collaboration. Gearbox Biosciences, based in Estonia, are pioneers in the antibiotic-free microbial production of biologics. This partnership aims to co-develop technologies that will revolutionize the manufacturing of pDNA, the ...

Evotec and Sandoz agree on potential sale of Just – Evotec Biologics Toulouse site

Continuation of strategic collaboration

31-Jul-2025 - Evotec SE announcedthe signing of a non-binding agreement with Sandoz AG regarding the potential sale of Just – Evotec Biologics EU, which owns the J.POD biologics manufacturing facility in Toulouse, France, and to grant access to its proprietary platform for integrated development and advanced ...